Fibrillar Aggregates of the Tumor Suppressor p53 Core Domain
- 8 July 2003
- journal article
- research article
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 42 (30) , 9022-9027
- https://doi.org/10.1021/bi034218k
Abstract
Alzheimer's disease, Parkinson's disease, cystic fibrosis, prion diseases, and many types of cancer are considered to be protein conformation diseases. Most of them are also known as amyloidogenic diseases due to the occurrence of pathological accumulation of insoluble aggregates with fibrillar conformation. Some neuroblastomas, carcinomas, and myelomas show an abnormal accumulation of the wild-type tumor suppressor protein p53 either in the cytoplasm or in the nucleus of the cell. Here we show that the wild-type p53 core domain (p53C) can form fibrillar aggregates after mild perturbation. Gentle denaturation of p53C by pressure induces fibrillar aggregates, as shown by electron and atomic force microscopies, by binding of thioflavin T, and by circular dichroism. On the other hand, heat denaturation produced granular-shaped aggregates. Annular aggregates similar to those found in the early aggregation stages of α-synuclein and amyloid-β were also observed by atomic force microscopy immediately after pressure treatment. Annular and fibrillar aggregates of p53C were toxic to cells, as shown by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] reduction assay. Interestingly, the hot-spot mutant R248Q underwent similar aggregation behavior when perturbed by pressure or high temperature. Fibrillar aggregates of p53C contribute to the loss of function of p53 and seed the accumulation of conformationally altered protein in some cancerous cells.Keywords
This publication has 20 references indexed in Scilit:
- Protein aggregation in disease: a role for folding intermediates forming specific multimeric interactionsJournal of Clinical Investigation, 2002
- Therapeutic strategies for human amyloid diseasesNature Reviews Drug Discovery, 2002
- High Pressure Refolding of Recombinant Human Growth Hormone from Insoluble AggregatesJournal of Biological Chemistry, 2001
- Getting p53 Out of the NucleusScience, 2001
- Evidence that wild-type p53 in neuroblastoma cells is in a conformation refractory to integration into the transcriptional complexOncogene, 2001
- Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapyOncogene, 2000
- In vitro analysis of the dominant negative effect of p53 mutantsJournal of Molecular Biology, 1998
- Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic MutationsScience, 1994
- Dissociation of a native dimer to a molten globule monomer: Effects of pressure and dilution on the association equilibrium of arc repressorJournal of Molecular Biology, 1992
- Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformationPublished by Elsevier ,1991